Related Experiment Videos
[Long-term prognosis of arterial lesions of Behçet's disease]
D U Le Thi Huong1, B Wechsler, J C Piette
1Service de médecine interne, Groupe hospitalier Pitié-Salpêtrière, Paris, France.
Insights
Patients with arterial lesions in Behçet's disease have a poor prognosis, requiring corticosteroids, surgery, and anticoagulants. Immunosuppressive drugs may improve outcomes but require further definition.
Area of Science:
- Vascular Medicine
- Rheumatology
- Immunology
Context:
- Behçet's disease is a rare multisystem inflammatory disorder.
- Arterial lesions are a serious complication of Behçet's disease.
- Limited data exists on long-term management and prognosis of arterial lesions in Behçet's disease.
Purpose:
- To analyze the long-term outcomes and treatment strategies for patients with arterial lesions in Behçet's disease.
Summary:
- A retrospective analysis of 25 patients with arterial lesions in Behçet's disease was conducted with a mean follow-up of 76 months.
- The study found a poor prognosis for these patients.
- Recommended treatments include corticosteroids, surgery, anti-aggregant or anticoagulant therapy, and prosthetic grafts over venous grafts.
- While this regimen does not eliminate relapse risk, combining immunosuppressive drugs with corticosteroids appears more effective than corticosteroids alone, though optimal therapeutic modalities require further investigation.
Impact:
- Highlights the poor prognosis associated with arterial lesions in Behçet's disease.
- Provides evidence-based recommendations for managing arterial lesions in Behçet's disease.
- Suggests a potential benefit of combining immunosuppressive drugs with corticosteroids for improved outcomes.
Abstract:
We analyzed the charts of 25 patients with arterial lesion in Behçet's disease with mean follow-up 76 months. We conclude that prognosis is poor. Corticosteroids and surgery if possible is needed, anti-aggregant or anticoagulants and prosthetic rather than venous graft are suitable. This therapy does not exclude the risk of relapse. Immunosuppressive drugs in addition to corticosteroids seem to be more efficient than corticosteroids alone but the therapeutic modalities need to be define.